Navigation Links
Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/14/2011

and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.  A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complem
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
3. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
4. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel, Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... developing octreotide capsules for the orphan condition acromegaly, ... ended June 30, 2015 and provided a corporate ... been a transformative time for Chiasma, as we ... announced that our first New Drug Application (NDA) ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
(Date:8/31/2015)... NEW YORK , Aug. 31, 2015  Dipexium ... company focused on the development and commercialization of Locilex® ... peptide, today announced plans to participate in four investor ... September 2, 2015 at the Sidoti & Company, LLC ... City . David P. Luci , President ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... YORK, July 8, 2011 The U.S. Food and ... Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for ... for active booster immunization against tetanus, diphtheria and pertussis ... vaccine approved for use in this age group.  With ...
... July 8, 2011 /PRNewswire-Asia/ -- Shenzhen Wuzhou Changlian International ... of multifunctional medical and industrial products, is pleased to ... Up to a 35% discount will be offered in ... promotional activity range from infrared thermometers , digital ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Enjoy Only One Thermometer in Various Domains 2
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm Enterprises LLC, (“CanAm”) is ... green cards (I-829 petition approval) from the USCIS through an investment in one ... of the EB-5 visa process for immigrant investors to become lawful permanent residents ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... borders seldom arise at the most convenient time for everyone involved. These occasions ... help. , Universal Translation Services has real people available to handle ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Network, the Premier Outcomes-Driven Provider Network. It is the first-ever, standardized, outcomes-driven ... the provision of quality addiction treatment and the utilization of resources to ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Elizabeth Callahan, ... one of the first in the area to offer RADIESSE® filler treatment for volume ... reduce the prominence of tendons and veins in the hands, delivering smooth, natural-looking results ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive U.S. importer ... physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of Osteoarthritis Knee ... Erick Salado, an orthopedic surgeon at South Florida Bone and Joint Institute, Inc. ...
Breaking Medicine News(10 mins):Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... about three-quarters of whites, Hispanics, CDC says , THURSDAY, ... powers of breast-feeding aren,t reaching black American women as ... study from the U.S. Centers for Disease Control and ... more than 80 percent of Hispanic mothers attempt to ...
... tumors escape the body,s natural immune surveillance has recently been ... The study shows how tumors can create a tolerant microenviroment ... features of lymph nodes. The discovery, published in Science ... 2010, underscores the role of the lymphatic system in cancer ...
... ... About Malaria Prevention Aboard an Eco-Friendly Bus , ... Atlanta, GA (Vocus) March 25, 2010 -- The United Nations Foundation,s ... announced today the launch of its Nothing But Nets Buzz Tour. The campaign will take ...
... ... cell-based strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s ... San Francisco, CA ... motor symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ...
... 33 percent higher risk of death, study finds, , ... do much better, in terms of survival, if they ... need, new research suggests. , The study found that ... need help from others have a 33 percent increased ...
... at the Eastern Virginia Medical School Strelitz Diabetes Center ... of Defense (DoD) Peer Reviewed Medical Research Program to ... Type 1 diabetes. David Taylor-Fishwick, PhD, ... Cell, Molecular and Islet Biology Laboratory, leads the team ...
Cached Medicine News:Health News:Black Women Least Likely to Breast-Feed in U.S. 2Health News:Black Women Least Likely to Breast-Feed in U.S. 3Health News:Tumors hide out from the immune system by mimicking lymph nodes 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:Accepting Help Improves Survival Among Diabetics 2Health News:Accepting Help Improves Survival Among Diabetics 3Health News:EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes 2
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... Lifestyle Gp is a ... multi-aspheric back surface. Through a ... surface curves, the LifeStyle Gp ... of add. Plus, its multi-aspheric ...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: